Vázquez-Ortega L, Camarena-Reynoso HR, Martínez JÁ, Hernández-Castellanos V, Leos-Acosta C, Shuck-Bello C, Cantellano-Orozco M, Morales-Montor J, Pacheco-Gabhler C, Calderón-Ferro F

Language: Spanish
References: 7
Page: 143-146
PDF size: 127.99 Kb.

ABSTRACT

Introduction: One of the most important aspects to be taken into account when treating cancer patients is quality of life. This facet has not been widely evaluated in Mexican patients and there are few international studies comparing quality of life in prostate cancer patients with different initial treatments.
Materials and methods: A validated quality of life questionnaire for prostate cancer patients was applied over a period of 5 consecutive months (from March to July 2008) to prostate cancer patients arriving for out- patient consultation. They had been under initial hormone treatment for at least 6 months, or had undergone radical surgery or received radiotherapy at least 1 year before. The patient, or a relative when necessary, answered the Expanded Prostate Cancer Index Composite (EPIC-2002) questionnaire after medical consultation. Questionnaires were graded and compared among the different treatment groups. Statistical analysis was carried out with ANOVA and Bonferroni and Dunnett tests.
Results: Fifty-seven patients meeting inclusion criteria participated in the study. Mean age was 71.5 years and mean prostate-specific antigen (PSA) was 95.67 ng/ml. Initial treatment was radical prostate surgery in 45.6% of patients, hormonal blockade in 42.1%, radiotherapy in 7% and surveillance in 5.3%. Mean follow-up was 47.7 months. Mean overall score of quality of life questionnaire was 3196 points: 856 points for urinary function, 1,180 for intestinal habits, 823 for hormonal function and 305 points for sexual function. When groups were divided into treatment subgroups of radical surgery, hormone therapy, radiotherapy and surveillance, a statistical tendency was seen only in the subgroup of patients having undergone radical prostatectomy with adjuvant radiotherapy and hormonal blockade.
Conclusions: No significant difference was found in questionnaire values, overall score or the different parameters studied. There was significant difference in the subgroup of patients treated with radical prostatectomy plus adjuvant radiotherapy and hormonal blockade.

REFERENCES

1. Registro Histopatológico de Neoplasias en México. 1998. Dirección General de Epidemiología y Estadística. Secretaría de Salud.

2. EAU. BPH Guidelines, 2008.

3. Wei J, Dunn R, Litwion M. Development and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men with Prostate Cancer. Urology 2000; 56: 899-905.

4. Way JT, Dunn RL, Sandler HM, Mclaughlin PW et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20(2): 557-66.

5. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical Prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007; 177(6): 2151-56.

6. Hollenbeck Brent, Dunn Rodney, Wei John. Determinants of long- term sexual HRQOL after radical prostatectomy measured by a validated instrument. J Urol 2003; 169: 1453-7.

7. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology 2002; 59: 480-4.